# ELF2

## Overview
ELF2, or E74 like ETS transcription factor 2, is a gene that encodes a member of the ETS family of transcription factors, which are pivotal in regulating gene expression related to various cellular processes, including cell growth, differentiation, and apoptosis. The ELF2 protein, characterized by its conserved ETS DNA-binding domain, functions primarily as a transcription factor, binding to specific DNA sequences to modulate the transcription of target genes. This protein exists in two major isoforms, ELF2A and ELF2B, which have distinct roles in gene regulation, with ELF2A generally acting as an activator and ELF2B as a repressor. ELF2 is predominantly localized in the nucleus and is involved in critical biological processes, particularly in hematopoietic tissues where it regulates early B and T cell development. The gene's involvement in cellular regulation and its potential implications in diseases such as cancer and neurodegenerative disorders underscore its significance in both normal physiology and pathology (Li2020&lt; Ahmad2018Clinical; Guan2017The).

## Structure
The ELF2 protein is a member of the ETS family of transcription factors, characterized by a conserved ETS DNA-binding domain that forms a winged helix-turn-helix structure. This domain allows ELF2 to bind to the core Ets motif 5′-GGAA/T-3′, facilitating its role in gene regulation (Guan2017The). ELF2 has two major isoforms, ELF2A and ELF2B, which arise from alternative promoter usage. These isoforms have distinct expression patterns and functional roles, with ELF2A primarily activating gene expression and ELF2B repressing it (Guan2017The).

The N- and C-termini of ELF2 are intrinsically disordered, which suggests their importance in recruiting binding partners and undergoing post-translational modifications such as phosphorylation (Guan2017The). ELF2B, in particular, lacks an intact transactivation domain, contributing to its unique antiproliferative and proapoptotic functions (Guan2017The). The ELF2 protein is predominantly localized in the nucleus, although some ELF2A is also found in the cytoplasm (Guan2017The). The structural study of ELF2 using cryo-electron microscopy revealed its binding to nucleosomes, which involves unwrapping nucleosomal DNA and exposing histone dimers, facilitating chromatin remodeling (Xiao2024Oriented).

## Function
ELF2 (E74 like ETS transcription factor 2) is a member of the ETS family of transcription factors, which play a crucial role in regulating gene expression involved in various cellular processes such as cell growth, differentiation, and apoptosis. In healthy human cells, ELF2 is primarily active in the nucleus, where it binds to specific DNA sequences to modulate the transcription of target genes. This regulation is essential for maintaining normal cellular functions and can impact organismal development and immune responses (Ahmad2018Clinical).

ELF2 has two major isoforms, ELF2A and ELF2B, which arise from alternative promoter usage. These isoforms have distinct roles, with ELF2A acting as an activator and ELF2B functioning as a repressor of gene expression. The balance between these isoforms is important for normal cellular function, particularly in early lymphocytic development. ELF2B has been shown to significantly reduce cell proliferation and clonogenic capacity, induce apoptosis, and minimally disrupt cell cycle kinetics, suggesting its potential role as a tumor suppressor (Guan2017The).

ELF2 is expressed in hematopoietic tissues and is involved in the regulation of early B and T cell development. It transcriptionally regulates genes such as Src-family receptor tyrosine kinases and immunoglobulin enhancers, which are crucial for lymphocytic development and differentiation (Guan2017The).

## Clinical Significance
Mutations and alterations in the ELF2 gene have been implicated in various diseases and conditions. In a study of a British family with Cerebellar Ataxia with Neuropathy and Vestibular Areflexia Syndrome (CANVAS), a missense variant in the ELF2 gene was identified. This variant, which results in an amino acid change (p.A4T), was found to segregate with the CANVAS phenotype and is predicted to be damaging due to its location in a highly conserved region of the ELF transcription factor domain. The study suggested that this mutation might affect the regulation of genes involved in neurodegenerative conditions, such as spinocerebellar ataxias, by altering the expression of ATXN2 and ELOVL5 genes (Ahmad2018Clinical).

In cancer research, ELF2 has been associated with nasopharyngeal carcinoma (NPC). The circRNA ZNF609 was found to regulate ELF2 expression, and its knockdown led to reduced cell proliferation and increased apoptosis in NPC cells. This suggests that ELF2 plays a role in promoting NPC cell growth, and targeting the circ-ZNF609/miR-188/ELF2 axis could offer potential therapeutic strategies (Li2020&lt; p&gt; CircRNA).

## Interactions
ELF2, a member of the ETS transcription factor family, participates in various interactions with proteins and nucleic acids that influence its regulatory functions. ELF2 isoforms, particularly ELF2A and ELF2B, interact with master hematopoietic regulators such as RUNX1 and LMO2, which are crucial for lymphocyte development and function (Guan2017The). ELF2B, known for its antiproliferative and proapoptotic roles, has a unique N-terminus that may interfere with normal ELF2 protein-protein interactions or recruit unique binding partners, enhancing its inhibitory function (Guan2017The).

ELF2 also interacts with the TERT promoter mutations, specifically C228T and C250T, where it binds to ETS motifs. This interaction is significant in the context of transcriptional regulation, although GABPA shows a stronger mutation-specific binding, potentially excluding ELF2 from binding in certain conditions (Makowski2016An).

In addition, ELF2 isoforms can bind to the same Ets target sites in DNA, sharing common co-factors, which suggests a level of functional redundancy and competition among ELF family members (Guan2017The). These interactions highlight ELF2's role in modulating gene expression and cellular processes through complex regulatory networks.


## References


[1. (Guan2017The) Fiona H. X. Guan, Charles G. Bailey, Cynthia Metierre, Patrick O’Young, Dadi Gao, Teh Liane Khoo, Jeff Holst, and John E. J. Rasko. The antiproliferative elf2 isoform, elf2b, induces apoptosis in vitro and perturbs early lymphocytic development in vivo. Journal of Hematology &amp; Oncology, March 2017. URL: http://dx.doi.org/10.1186/s13045-017-0446-7, doi:10.1186/s13045-017-0446-7. This article has 17 citations.](https://doi.org/10.1186/s13045-017-0446-7)

[2. (Ahmad2018Clinical) Hena Ahmad, Teresa Requena, Lidia Frejo, Marien Cobo, Alvaro Gallego-Martinez, Francisco Martin, Jose A. Lopez-Escamez, and Adolfo M. Bronstein. Clinical and functional characterization of a missense elf2 variant in a canvas family. Frontiers in Genetics, March 2018. URL: http://dx.doi.org/10.3389/fgene.2018.00085, doi:10.3389/fgene.2018.00085. This article has 22 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2018.00085)

[3. (Makowski2016An) Matthew M. Makowski, Esther Willems, Jun Fang, Jiyeon Choi, Tongwu Zhang, Pascal W. T. C. Jansen, Kevin M. Brown, and Michiel Vermeulen. An interaction proteomics survey of transcription factor binding at recurrent tert promoter mutations. PROTEOMICS, 16(3):417–426, January 2016. URL: http://dx.doi.org/10.1002/pmic.201500327, doi:10.1002/pmic.201500327. This article has 51 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/pmic.201500327)

4. (Xiao2024Oriented) Oriented nucleosome binding by the pioneer factor ELF2. This article has 0 citations.